We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+5.08%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.49B
AUM Growth
+$37.4M
(+1.5%)
Cap. Flow
-$505M
Cap. Flow
% of AUM
-20.29%
Top 10 Holdings %
Top 10 Hldgs %
34.18%
Holding
156
New
33
Increased
30
Reduced
32
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$84.9M |
| 2 |
eHealth
EHTH
|
+$41.7M |
| 3 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$35.2M |
| 4 |
AGN
Allergan Inc
AGN
|
+$34M |
| 5 |
ITMN
INTERMUNE INC
ITMN
|
+$26.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$87.6M |
| 2 |
Labcorp
LH
|
+$56.3M |
| 3 |
Merck
MRK
|
+$27.1M |
| 4 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$26.4M |
| 5 |
Quest Diagnostics
DGX
|
+$25.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.33% |
| 2 | Financials | 2.57% |
| 3 | Technology | 1.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Smith & Nephew
SNN
$12.8B
| $670K | 0.03% |
+18,750
| New | +$614K |
|
102
TherapeuticsMD
TXMD
$24.4M
| $492K | 0.02% |
2,224
-5,297
| -70% | -$1.18M |
|
103
Icon
ICLR
$12.8B
| $471K | 0.02% |
+10,000
| New | +$432K |
|
|
IMRS
104
DELISTED
IMRIS INC COMMON SHARES (CANADA)
IMRS
| $460K | 0.02% |
+407,392
| New | +$486K |
|
105
Prothena Corp
PRTA
$454M
| $451K | 0.02% |
+20,000
| New | +$500K |
|
106
Tenax Therapeutics
TENX
$416M
| $446K | 0.02% |
3
-14
| -82% | -$2.16M |
|
107
Perrigo
PRGO
$1.47B
| $364K | 0.01% |
+2,500
| New | +$354K |
|
108
Opko Health
OPK
$906M
| $332K | 0.01% |
+37,500
| New | +$327K |
|
|
MDRX
109
DELISTED
Veradigm Inc. Common Stock
MDRX
| $289K | 0.01% |
+18,000
| New | +$281K |
|
110
Precipio
PRPO
$41.8M
| $266K | 0.01% |
+8
| New | +$278K |
|
111
Alkermes
ALKS
$8.62B
| $201K | 0.01% |
+4,000
| New | +$184K |
|
|
OREX
112
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $152K | 0.01% |
+2,465
| New | +$143K |
|
|
ACHN
113
DELISTED
Achillion Pharmaceuticals
ACHN
| $95K | ﹤0.01% |
12,500
-80,304
| -87% | -$320K |
|
114
Agilent Technologies
A
$36.8B
| – | – |
-34,950
| Closed | -$1.4M |
|
115
Baxter International
BAX
$11.4B
| – | – |
-156,485
| Closed | -$6.25M |
|
116
BioCryst Pharmaceuticals
BCRX
$2.32B
| – | – |
-907,920
| Closed | -$9.61M |
|
117
Biogen
BIIB
$29.5B
| – | – |
-11,750
| Closed | -$3.59M |
|
118
Centene
CNC
$32.5B
| – | – |
-499,180
| Closed | -$7.77M |
|
|
119
Quest Diagnostics
DGX
$23B
| – | – |
-440,303
| Closed | -$25.5M |
|
120
Exelixis
EXEL
$14B
| – | – |
-400,000
| Closed | -$1.38M |
|
121
Gyre Therapeutics
GYRE
$656M
| – | – |
-783
| Closed | -$2.93M |
|
|
HOLX
122
DELISTED
Hologic
HOLX
| – | – |
-42,500
| Closed | -$914K |
|
123
Illumina
ILMN
$27.9B
| – | – |
-18,193
| Closed | -$2.63M |
|
124
PUT
MannKind Corp
MNKD
$1.23B
| – | – |
-200,000
| Closed | -$4.02M |
|
125
Molina Healthcare
MOH
$12B
| – | – |
-451,391
| Closed | -$17M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q2 2014 Portfolio in Review
As of Q2 2014, Deerfield Management held 156 positions worth $2.49B, up 1.5% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Deerfield Management withdrew a net $505M in Q2 2014, closing 28 positions and reducing 32 holdings. Its most notable exit was Merck, an estimated $27.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 44% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $23.1M.
- Deerfield Management's largest Q2 2014 buy was TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK: 1,482,666 shares worth $23.1M.
- Deerfield Management added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $84.9M increase.
- Deerfield Management's biggest Q2 2014 reduction was QUESTCOR PHARMA INC, cutting an estimated $87.6M.
- Deerfield Management fully exited Merck in Q2 2014, selling an estimated $27.1M.
- Deerfield Management's ten largest holdings make up 34% of its $2.49B portfolio in Q2 2014.
- Deerfield Management opened 33 new positions and closed 28 in Q2 2014.
- Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.49B.
Based on Deerfield Management's 13F filing for Q2 2014, filed 14 Aug 2014.